



Supplementary Figure S2



Supplementary Figure S2. *OX40L, CD80 and CD86 mRNA-CART treatment induce long lasting protection against re-challenge with the same tumor cell line.* mRNA-CART treated mice that had completely rejected the tumor were re-challenged with 10^7 A20-cells s.c. (orange, n=5) and compared to naïve mice (black., n=5).

Supplementary Figure S3



Supplementary Figure S3. *OX40L, CD80 and CD86 mRNA-CART treatment do not result in long term elevated levels of proinflammatory cytokines in serum of treated mice.* Mice treated with mRNA-CARTs were assayed for serum levels of pro-inflammatory cytokines 22 days after last treatment. Aged matched un-treated mice were included as controls. MFI = Mean fluorescent intensity.